AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction

Phase 2

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: PF-00446687
Drug: Placebo
Drug: Sildenafil

First Posted Date: 2009-03-17

Last Posted Date: 2009-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 39

Registration Number: NCT00862888

Locations: 🇬🇧
Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Treatment A
Drug: Treatment C
Drug: Treatment B

First Posted Date: 2009-03-17

Last Posted Date: 2009-06-24

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00862667

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State

Phase 1

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Pharmacokinetics

First Posted Date: 2009-03-13

Last Posted Date: 2009-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT00861458

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CP- 690,550 and Tacrolimus
Drug: CP- 690,550 and Cyclosporine

First Posted Date: 2009-03-12

Last Posted Date: 2009-08-13

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00860496

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects

Phase 4

Completed

Conditions: Falciparum Malaria

Interventions: Drug: Flavoquine®, Camoquin® Suspension

First Posted Date: 2009-03-11

Last Posted Date: 2010-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT00859807

Locations: 🇮🇳
Pfizer Investigational Site, Navi Mumbai, Maharashtra, India

Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Etanercept

First Posted Date: 2009-03-10

Last Posted Date: 2013-09-11

Lead Sponsor: Pfizer

Target Recruit Count: 91

Registration Number: NCT00858780

Locations: 🇸🇪
Pfizer Investigational Site, Uppsala, Sweden

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: pegaptanib sodium

First Posted Date: 2009-03-09

Last Posted Date: 2012-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 86

Registration Number: NCT00858208

Locations: 🇬🇷
Pfizer Investigational Site, Xanthi, Greece

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

Phase 2

Completed

Conditions: Overactive Bladder
Neurogenic Detrusor Overactivity

Interventions: Drug: Fesoterodine

First Posted Date: 2009-03-09

Last Posted Date: 2011-11-24

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT00857896

Locations: 🇺🇸
Pfizer Investigational Site, Liberty Township, Ohio, United States

Non Interventional Study For Patients Treated With Somavert®

Completed

Conditions: Acromegaly

Interventions: Other: Non Interventional Observation

First Posted Date: 2009-03-09

Last Posted Date: 2009-09-02

Lead Sponsor: Pfizer

Target Recruit Count: 311

Registration Number: NCT00858143

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: 150 mg Suspension
Drug: 150 mg Tablet
Drug: 30 mg Suspension
Drug: 30 mg Tablet
Drug: 400 mg Suspension
Drug: 400 mg Tablet
Drug: 5 mg Suspension
Drug: 5 mg Tablet
Drug: 750 mg Suspension
Drug: 750 mg Tablet

First Posted Date: 2009-03-06

Last Posted Date: 2018-12-07

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00857571

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Home Terms & Conditions Privacy Policy